Prevalence at Diagnosis & Last Followup, 20-Year Event-Free Survival, Predictors Included in the Multivariate Cox Regression Model, HRs, and 95% CIs for Individual Endocrine Events
| Endocrine Event . | n (%) . | 20-Year Event-Free Survival (95% CI) . | Independent Predictors . | Adjusted HR (95% CI) . | P . | |
|---|---|---|---|---|---|---|
| At Diagnosis . | At Last Followup . | |||||
| GHD | 1 (0.6) | 67 (40.3) | 39.2 (27.2–51.2) | Any radiotherapy | 5.76 (2.93–11.32) | <.001 |
| Treatment era (vs 1980–1996) | ||||||
| 1997–2004 | 0.89 (0.50–1.58) | .682 | ||||
| 2005–2010 | 2.48 (1.29–4.79) | .007 | ||||
| Primary radiotherapy | 2.48 (1.36–4.52) | .003 | ||||
| No. surgeries | 1.09 (1.04–1.14) | <.001 | ||||
| CPP | 14/123 (11.4) | 32/123 (26.0) | 69.7 (60.8–78.6) | Hypothalamic involvement | 4.42 (1.97–9.92) | <.001 |
| Female sex | 0.43 (0.21–0.90) | .024 | ||||
| Any chemotherapy | 0.42 (0.20–0.90) | .026 | ||||
| GnD | 1/7 (14.3) | 21/103 (20.4) | 58.4 (39.4–77.4) | Hypothalamic involvement | 5.09 (1.95–13.31) | .001 |
| Primary radiotherapy | 3.27 (1.35–7.94) | .009 | ||||
| ACTHD | 1 (0.6) | 22 (13.3) | 75.6 (65.2–86.0) | Diencephalic syndrome | 15.72 (4.38–56.39) | <.001 |
| Primary radiotherapy | 5.16 (2.12–12.57) | <.001 | ||||
| Female sex | 0.30 (0.12–0.74) | .009 | ||||
| Any chemotherapy | 0.30 (0.10–0.92) | .035 | ||||
| TSHD | 2 (1.2) | 22 (13.3) | 75.3 (64.6–86.0) | Hypothalamic involvement | 7.18 (2.41–21.38) | <.001 |
| HyperPRL | 5 (3.0) | 5 (3.0) | 78.1 (64.8–91.4) | — | — | — |
| PPD | 4 (2.4) | 12 (7.2) | 79.2 (69.8–88.7) | Hypothalamic involvement | 5.82 (1.64–20.67) | .006 |
| 1 CDI | 7 CDI | 86.1 (71.6–100.0) | Any resection | 4.61 (1.39–15.34) | .013 | |
| 2 SIADH | 2 SIADH | 86.8 (79.0–94.6) | Treatment era (vs 1990–1996) | |||
| 1 CSW | 3 CSW | 91.4 (84.4–98.5) | 1997–2004 | 0.19 (0.04–0.87) | .032 | |
| 2005–2010 | 1.25 (0.38–4.08) | .716 | ||||
| Obesity | 23 (13.9) | 54 (32.5) | 50.2 (35.4–65.1) | — | — | — |
| Insulin resistance | 0 (0.0) | 16 (9.6) | 73.1 (55.9–90.3) | Primary decompression Primary radiotherapy | 3.96 (1.43–10.93)3.91 (1.42–10.80) | .008.009 |
| Endocrine Event . | n (%) . | 20-Year Event-Free Survival (95% CI) . | Independent Predictors . | Adjusted HR (95% CI) . | P . | |
|---|---|---|---|---|---|---|
| At Diagnosis . | At Last Followup . | |||||
| GHD | 1 (0.6) | 67 (40.3) | 39.2 (27.2–51.2) | Any radiotherapy | 5.76 (2.93–11.32) | <.001 |
| Treatment era (vs 1980–1996) | ||||||
| 1997–2004 | 0.89 (0.50–1.58) | .682 | ||||
| 2005–2010 | 2.48 (1.29–4.79) | .007 | ||||
| Primary radiotherapy | 2.48 (1.36–4.52) | .003 | ||||
| No. surgeries | 1.09 (1.04–1.14) | <.001 | ||||
| CPP | 14/123 (11.4) | 32/123 (26.0) | 69.7 (60.8–78.6) | Hypothalamic involvement | 4.42 (1.97–9.92) | <.001 |
| Female sex | 0.43 (0.21–0.90) | .024 | ||||
| Any chemotherapy | 0.42 (0.20–0.90) | .026 | ||||
| GnD | 1/7 (14.3) | 21/103 (20.4) | 58.4 (39.4–77.4) | Hypothalamic involvement | 5.09 (1.95–13.31) | .001 |
| Primary radiotherapy | 3.27 (1.35–7.94) | .009 | ||||
| ACTHD | 1 (0.6) | 22 (13.3) | 75.6 (65.2–86.0) | Diencephalic syndrome | 15.72 (4.38–56.39) | <.001 |
| Primary radiotherapy | 5.16 (2.12–12.57) | <.001 | ||||
| Female sex | 0.30 (0.12–0.74) | .009 | ||||
| Any chemotherapy | 0.30 (0.10–0.92) | .035 | ||||
| TSHD | 2 (1.2) | 22 (13.3) | 75.3 (64.6–86.0) | Hypothalamic involvement | 7.18 (2.41–21.38) | <.001 |
| HyperPRL | 5 (3.0) | 5 (3.0) | 78.1 (64.8–91.4) | — | — | — |
| PPD | 4 (2.4) | 12 (7.2) | 79.2 (69.8–88.7) | Hypothalamic involvement | 5.82 (1.64–20.67) | .006 |
| 1 CDI | 7 CDI | 86.1 (71.6–100.0) | Any resection | 4.61 (1.39–15.34) | .013 | |
| 2 SIADH | 2 SIADH | 86.8 (79.0–94.6) | Treatment era (vs 1990–1996) | |||
| 1 CSW | 3 CSW | 91.4 (84.4–98.5) | 1997–2004 | 0.19 (0.04–0.87) | .032 | |
| 2005–2010 | 1.25 (0.38–4.08) | .716 | ||||
| Obesity | 23 (13.9) | 54 (32.5) | 50.2 (35.4–65.1) | — | — | — |
| Insulin resistance | 0 (0.0) | 16 (9.6) | 73.1 (55.9–90.3) | Primary decompression Primary radiotherapy | 3.96 (1.43–10.93)3.91 (1.42–10.80) | .008.009 |
Abbreviation: HyperPRL, hyperprolactinemia.
For univariate HRs see Supplemental Table 4.
Bold values indicate P < .05.
Prevalence at Diagnosis & Last Followup, 20-Year Event-Free Survival, Predictors Included in the Multivariate Cox Regression Model, HRs, and 95% CIs for Individual Endocrine Events
| Endocrine Event . | n (%) . | 20-Year Event-Free Survival (95% CI) . | Independent Predictors . | Adjusted HR (95% CI) . | P . | |
|---|---|---|---|---|---|---|
| At Diagnosis . | At Last Followup . | |||||
| GHD | 1 (0.6) | 67 (40.3) | 39.2 (27.2–51.2) | Any radiotherapy | 5.76 (2.93–11.32) | <.001 |
| Treatment era (vs 1980–1996) | ||||||
| 1997–2004 | 0.89 (0.50–1.58) | .682 | ||||
| 2005–2010 | 2.48 (1.29–4.79) | .007 | ||||
| Primary radiotherapy | 2.48 (1.36–4.52) | .003 | ||||
| No. surgeries | 1.09 (1.04–1.14) | <.001 | ||||
| CPP | 14/123 (11.4) | 32/123 (26.0) | 69.7 (60.8–78.6) | Hypothalamic involvement | 4.42 (1.97–9.92) | <.001 |
| Female sex | 0.43 (0.21–0.90) | .024 | ||||
| Any chemotherapy | 0.42 (0.20–0.90) | .026 | ||||
| GnD | 1/7 (14.3) | 21/103 (20.4) | 58.4 (39.4–77.4) | Hypothalamic involvement | 5.09 (1.95–13.31) | .001 |
| Primary radiotherapy | 3.27 (1.35–7.94) | .009 | ||||
| ACTHD | 1 (0.6) | 22 (13.3) | 75.6 (65.2–86.0) | Diencephalic syndrome | 15.72 (4.38–56.39) | <.001 |
| Primary radiotherapy | 5.16 (2.12–12.57) | <.001 | ||||
| Female sex | 0.30 (0.12–0.74) | .009 | ||||
| Any chemotherapy | 0.30 (0.10–0.92) | .035 | ||||
| TSHD | 2 (1.2) | 22 (13.3) | 75.3 (64.6–86.0) | Hypothalamic involvement | 7.18 (2.41–21.38) | <.001 |
| HyperPRL | 5 (3.0) | 5 (3.0) | 78.1 (64.8–91.4) | — | — | — |
| PPD | 4 (2.4) | 12 (7.2) | 79.2 (69.8–88.7) | Hypothalamic involvement | 5.82 (1.64–20.67) | .006 |
| 1 CDI | 7 CDI | 86.1 (71.6–100.0) | Any resection | 4.61 (1.39–15.34) | .013 | |
| 2 SIADH | 2 SIADH | 86.8 (79.0–94.6) | Treatment era (vs 1990–1996) | |||
| 1 CSW | 3 CSW | 91.4 (84.4–98.5) | 1997–2004 | 0.19 (0.04–0.87) | .032 | |
| 2005–2010 | 1.25 (0.38–4.08) | .716 | ||||
| Obesity | 23 (13.9) | 54 (32.5) | 50.2 (35.4–65.1) | — | — | — |
| Insulin resistance | 0 (0.0) | 16 (9.6) | 73.1 (55.9–90.3) | Primary decompression Primary radiotherapy | 3.96 (1.43–10.93)3.91 (1.42–10.80) | .008.009 |
| Endocrine Event . | n (%) . | 20-Year Event-Free Survival (95% CI) . | Independent Predictors . | Adjusted HR (95% CI) . | P . | |
|---|---|---|---|---|---|---|
| At Diagnosis . | At Last Followup . | |||||
| GHD | 1 (0.6) | 67 (40.3) | 39.2 (27.2–51.2) | Any radiotherapy | 5.76 (2.93–11.32) | <.001 |
| Treatment era (vs 1980–1996) | ||||||
| 1997–2004 | 0.89 (0.50–1.58) | .682 | ||||
| 2005–2010 | 2.48 (1.29–4.79) | .007 | ||||
| Primary radiotherapy | 2.48 (1.36–4.52) | .003 | ||||
| No. surgeries | 1.09 (1.04–1.14) | <.001 | ||||
| CPP | 14/123 (11.4) | 32/123 (26.0) | 69.7 (60.8–78.6) | Hypothalamic involvement | 4.42 (1.97–9.92) | <.001 |
| Female sex | 0.43 (0.21–0.90) | .024 | ||||
| Any chemotherapy | 0.42 (0.20–0.90) | .026 | ||||
| GnD | 1/7 (14.3) | 21/103 (20.4) | 58.4 (39.4–77.4) | Hypothalamic involvement | 5.09 (1.95–13.31) | .001 |
| Primary radiotherapy | 3.27 (1.35–7.94) | .009 | ||||
| ACTHD | 1 (0.6) | 22 (13.3) | 75.6 (65.2–86.0) | Diencephalic syndrome | 15.72 (4.38–56.39) | <.001 |
| Primary radiotherapy | 5.16 (2.12–12.57) | <.001 | ||||
| Female sex | 0.30 (0.12–0.74) | .009 | ||||
| Any chemotherapy | 0.30 (0.10–0.92) | .035 | ||||
| TSHD | 2 (1.2) | 22 (13.3) | 75.3 (64.6–86.0) | Hypothalamic involvement | 7.18 (2.41–21.38) | <.001 |
| HyperPRL | 5 (3.0) | 5 (3.0) | 78.1 (64.8–91.4) | — | — | — |
| PPD | 4 (2.4) | 12 (7.2) | 79.2 (69.8–88.7) | Hypothalamic involvement | 5.82 (1.64–20.67) | .006 |
| 1 CDI | 7 CDI | 86.1 (71.6–100.0) | Any resection | 4.61 (1.39–15.34) | .013 | |
| 2 SIADH | 2 SIADH | 86.8 (79.0–94.6) | Treatment era (vs 1990–1996) | |||
| 1 CSW | 3 CSW | 91.4 (84.4–98.5) | 1997–2004 | 0.19 (0.04–0.87) | .032 | |
| 2005–2010 | 1.25 (0.38–4.08) | .716 | ||||
| Obesity | 23 (13.9) | 54 (32.5) | 50.2 (35.4–65.1) | — | — | — |
| Insulin resistance | 0 (0.0) | 16 (9.6) | 73.1 (55.9–90.3) | Primary decompression Primary radiotherapy | 3.96 (1.43–10.93)3.91 (1.42–10.80) | .008.009 |
Abbreviation: HyperPRL, hyperprolactinemia.
For univariate HRs see Supplemental Table 4.
Bold values indicate P < .05.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
